Advanced Radiation Therapy and Radiobiology for Hepatocellular Carcinoma
Advances in systemic therapy have transformed the care of patients with hepatocellular carcinoma (HCC) in recent years, including with immunotherapy and targeted agents. Recently, stereotactic body radiation therapy (SBRT) followed by sorafenib showed an overall survival advantage over standard of care (at the time of the original study design) sorafenib. SBRT is the first local therapy for patients with advanced stage HCC to show an OS improvement over sorafenib in a phase III trial, and this Article Collection highlights advances in the clinical delivery of radiation for this disease and new insights into the effects of radiation on the liver.
Guest advisors
Dr. Eugene Koay(MD Anderson Cancer Center)
Dr. Eugene Koay is a physician scientist at The University of Texas MD Anderson Cancer Center, who specializes in radiation therapy for patients with hepatobiliary and pancreatic cancers, and develops applications of the physical sciences to cancer for the purposes of early detection, biomarker development, and therapeutic management. He leads the Cancer Physics and Engineering Laboratory at MD Anderson.
Dr. Jennifer Y. Wo(Harvard Medical School & Massachusetts General Hospital)
Dr. Wo is Associate Professor of Radiation Oncology at Harvard Medical School and clinical attending physician in radiation oncology at Massachusetts General Hospital. Involved in both patient care and clinical research, her research involves prospective clinical trials with advanced radiation and integration with targeted therapies.